Semaglutide 2.4mg for Low Responders After Bariatric Surgery

Study acronym: SEABAR
StatusUnknown
PhasePhase 4
Started

Record status This record was last updated March 1, 2024 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Feb 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In 20 - 30% of the patients, the low responders, sufficient weight loss is not achieved after bariatric surgery. Secondary and/or tertiary bariatric procedures can lead to successful weight loss and resolution of comorbid conditions though, morbidity and mortality rates of these procedures are high. Therefore, additional pharmacotherapy has been suggested. Semaglutide is one of the medications that might improve outcome in the post-bariatric population. Semaglutide is a Glucagon-like peptide-1 (GLP-1) receptor analogue developed to treat type 2 diabetes. It causes glucose-dependent insulin secretion, promotes satiety and inhibits glucagon secretion. In obese (non-bariatric) patients, semaglutide has shown to improve glycemic control, decrease blood pressure, lower cardiovascular risk, and decrease body weight.
Trial Details
NCT Number NCT06287307
Lead Sponsor Zuyderland Medisch Centrum
Collaborators: Nederlandse Obesitas Kliniek
Conditions
(from sponsor)		 Obesity, Obesity, Morbid, Weight Gain
Related terms Obesity, Obesity, Morbid, Weight Gain, Weight Loss
Enrollment 152 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov